A phase 1/2 trial of CLIO-8221 in advanced solid tumours, run by Callio Therapeutics, now recruiting.
Study in Advanced Solid Tumor Patients is a phase 1/2 interventional study registered as NCT07300943 by Callio Therapeutics, with 306 participants planned, started 2026-03-19 and due to reach its primary completion in 2027-12-31. Interventions recorded: CLIO-8221.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.